Condition: Lymphoma, T-Cell · NK-LGL Leukemia · T-LGL Leukemia · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Indolent T/NK-cell lymphomas are a heterogeneous group of lymphoproliferative diseases originating from T/NK cells, characterized by slow growth and proliferation, but currently remain incurable. For indolent T/NK-cell lymphomas that are unresponsive to first-line treatment, there are few treatment options available and the prognosis is poor. This study is an open-label, prospective clinical trial aimed at evaluating the feasibility, efficacy, and safety of PI3K inhibitors in the treatment of relapsed/refractory indolent T/NK-cell lymphomas. Patients will be treated with Golidocitnib, with an expected overall response rate of 60% for JAK1 inhibitor Golidocitnib treatment.
This description comes directly from the study's public registry record.
Shuhua Yi, Doctor · 86-22-23909106 · yishuhua@ihcams.ac.cn
Lugui Qiu, Doctor · 86-22-23909172 · qiulg@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology & Blood Diseases Hospital, China | Tianjin, Tianjin Municipality, China | Recruiting |
| Institute of Hematology & Blood Diseases Hospital | Tianjin, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716658